METHOD FOR MANUFACTURING A BIOCOMPATIBLE FLUID COMPRISING A POWDER OF MAGNETIC PARTICLES, BIOCOMPATIBLE FLUID COMPRISING A POWDER OF MAGNETIC PARTICLES

• US 20190307903A1
• Filed: 04/05/2019
• Published: 10/10/2019
• Est. Priority Date: 04/05/2018
• Status: Abandoned Application

• Current Assignee: Commissariat a L'Energie Atomique (AES Corporation), Centre National De La Recherche Scientifique
• Original Assignee: Commissariat a L'Energie Atomique (AES Corporation), Centre National De La Recherche Scientifique
• Inventors: MOREL, Robert, DIENY, Bernard, JOISTEN, Helene
• Application Number:
  US16/376,297
• Publication Number:
  US 20190307903A1
• Time in Patent Office: Days
• CPC Class Codes: A61B 5/0051 by applying vibrations
• CPC Class Codes: A61B 5/0515 Magnetic particle imaging
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61K 49/0093 Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
• CPC Class Codes: A61K 49/101 the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: B22F 1/16 Metallic particles coated with a non-metal coated with lubricating or binding agents or with organic material B22F1/10
• CPC Class Codes: H01F 1/0054 Coated nanoparticles, e.g. nanoparticles coated with organic surfactant

Abstract

A method for manufacturing a biocompatible fluid including a powder of magnetic particles of elongated shape having a magnetic shape anisotropy and having a final granulometry, the final granulometry being defined by a first average size of the particles in a first direction and a second average size in a second direction different from the first direction, the final granulometry further being defined by a first distribution width of the first sizes and a second distribution width of the second sizes, the method including from a powder of magnetic particles having an initial granulometry different from the final granulometry, modification of the initial granulometry by milling and/or by sintering of the powder until the final granulometry is obtained; introduction of the powder of magnetic particles into a biocompatible fluid.

Claims

1. A method for manufacturing a biocompatible fluid comprising a powder of magnetic particles of elongated shape having a magnetic shape anisotropy and having a final granulometry, said final granulometry being defined by a first average size of the particles in a first direction and a second average size in a second direction different from the first direction, the second average size being less than 1.5 times the first average size, said final granulometry further being defined by a first distribution width of the first sizes and a second distribution width of the second sizes, said method comprising:

from a powder of magnetic particles having an initial granulometry different from the final granulometry, modifying the initial granulometry by milling and/or by sintering of the powder until the final granulometry is obtained;

introducing the powder of magnetic particles into a biocompatible fluid, the first average size of the magnetic particles being comprised between 0.2 μ

m and 10 μ

m and the distribution width of the first sizes representing at least 30% of the value of the first average size.

2. The method for manufacturing a biocompatible fluid according to claim 1, wherein the first average size of the particles is comprised between 0.2 μ

m and 5 μ

m.

3. The method for manufacturing a biocompatible fluid according to claim 1, wherein during the modifying of the initial granulometry, the milling of the powder of magnetic particles having the initial granulometry is followed by the sintering of the powder resulting from the milling or the sintering of the powder of magnetic particles having the initial granulometry is followed by the milling of the powder resulting from the sintering.

4. The method for manufacturing a biocompatible fluid according to claim 1, wherein the powder of final granulometry is of same chemical nature as the powder of initial granulometry.

5. The method for manufacturing a biocompatible fluid according to claim 1, further comprising performing a chemical functionalisation of the particles.

6. The method for manufacturing a biocompatible fluid according to claim 5, wherein the chemical functionalisation comprises an encapsulation of at least one part of the particles in an inorganic layer.

7. The method for manufacturing a biocompatible fluid according to claim 6, wherein the inorganic layer is made of silica.

8. The method for manufacturing a biocompatible fluid according to claim 5, wherein the chemical functionalisation includes grafting polymers on the surface of the particles or of the inorganic layer.

9. The method for manufacturing a biocompatible fluid according to claim 8, wherein the grafted polymer includes polyethylene glycol (PEG).

10. The method for manufacturing a biocompatible fluid according to claim 1, wherein the magnetic particles are grains including a metal oxide.

11. The method for manufacturing a biocom patible fluid according to claim 1, further comprising refining the size distribution of the particles in solution.

12. A biocompatible fluid comprising a powder of magnetic particles of elongated shape having a magnetic shape anisotropy and having a final granulometry, said final granulometry being defined by a first average size of the particles in a first direction and a second average size in a second direction different from the first direction, the second average size being less than 1.5 times the first average size, said final granulometry further being defined by a first distribution width of the first sizes and a second distribution width of the second sizes, the first average size of the magnetic particles being comprised between 0.2 μ

m and 10 μ

m and the distribution width of the first sizes representing at least 30% of the value of the first average size.